Ocular Therapeutix, Inc. (NASDAQ: OCUL), an integrated biopharmaceutical company specializing in retinal disease treatments, announced its financial results for the fourth quarter and full year ending December 31, 2025. The company also highlighted significant milestones in their ongoing clinical trials, particularly the upcoming results from the SOL-1 Phase 3 trial of AXPAXLI™, intended for the treatment of wet age-related macular degeneration (wet AMD).

1. Business Highlights

Upcoming SOL-1 Phase 3 Trial Results

Ocular Therapeutix is set to present topline results from its SOL-1 Phase 3 superiority clinical trial during the 49th Macula Society Annual Meeting scheduled for February 25-28, 2026. This trial, conducted under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA), aims to establish AXPAXLI as a potential superior treatment compared to a single dose of aflibercept (2 mg) for wet AMD. The company reported strong patient retention and adherence to the trial protocol, although results remain under wraps until the meeting.

Drug Application Plans and Other Trials

If the results from the SOL-1 trial are favorable, Ocular Therapeutix plans to file a New Drug Application (NDA) for AXPAXLI based on the Week 52 data. The company intends to utilize the 505(b)(2) approval pathway, which may expedite the NDA review process by up to two months.

The company also reported that the SOL-R non-inferiority trial completed its randomization in December 2025, exceeding its target enrollment of 555 subjects. The topline data from this trial is now expected in the first quarter of 2027. Furthermore, the SOL-X open-label extension trial is anticipated to begin in the second quarter of 2026, allowing subjects from SOL-1 and SOL-R to participate in long-term safety follow-ups.

In addition, Ocular Therapeutix is making strides with its HELIOS-3 Phase 3 trial for diabetic retinopathy, which commenced in November 2025. This trial seeks to broaden the label for AXPAXLI in diabetic retinal diseases.

Financial Position

Ocular Therapeutix recently raised approximately $475 million in gross proceeds from an equity offering in September 2025, with net proceeds of around $445.6 million. This funding is expected to support operational needs through 2028.

2. Financial Results Overview

Q4 and Full Year 2025 Financial Performance

For the fourth quarter of 2025, Ocular Therapeutix reported total net revenues of $13.3 million, reflecting a 22.4% decline from $17.1 million in the same period in 2024. For the full year 2025, total net revenue decreased by 18.5%, totaling $52.0 million compared to $63.7 million in 2024. Despite achieving the highest annual unit volume of DEXTENZA in 2025, the company faced challenges with reimbursement rates that negatively impacted net revenue.

In terms of expenditures, research and development (R&D) expenses rose to $50.8 million for the fourth quarter, up from $41.0 million in Q4 2024. This increase is attributed to heightened clinical trial activities related to AXPAXLI. R&D expenses for the full year 2025 totaled $197.1 million, significantly up from $127.6 million in 2024.

Selling and marketing expenses also saw an increase, reaching $13.0 million in Q4 2025, compared to $10.8 million in the prior year. This reflects the company’s investment in expanding its commercial team in preparation for AXPAXLI’s potential market entry.

Net Loss

Ocular Therapeutix reported a net loss of $(64.7) million for the fourth quarter of 2025, equating to a loss of $(0.29) per share, consistent with the same loss per share reported in Q4 2024. For the full year, the net loss was $(265.9) million, or $(1.42) per share, compared to a net loss of $(193.5) million, or $(1.22) per share in 2024.

Cash Position

As of December 31, 2025, Ocular Therapeutix had total cash and cash equivalents of $737.1 million, which the company believes will suffice to fund its operations, including trial expenses, through 2028.

3. Conclusion

Ocular Therapeutix's recent press release indicates a company in a pivotal phase of development, with promising clinical trials on the horizon for AXPAXLI. While financial results show a decline in revenue, the significant cash reserves and upcoming trial data may position the company favorably for future growth and product approval in the competitive biopharmaceutical landscape. Investors will be closely watching the results of the SOL-1 trial, which could be a key driver for Ocular’s prospects in the retinal disease market.

Original press release